AFC
ANIP icon

Ares Financial Consulting’s ANI Pharmaceuticals ANIP Stock Holding History

Ares Financial Consulting’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$911 Hold
11
– – ﹤0.01% 1019
2026
Q1 		$836 Hold
11
– – ﹤0.01% 979
2025
Q4 		$868 Buy
+11
New +$952 ﹤0.01% 788

Other funds holding ANIP

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
MMA
Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
RL
Ruffer LLP London, United Kingdom $2.83B AUM 30.34% 1-Year Est. Return

Ares Financial Consulting's ANIP Position: Q2 2026 in Review

Ares Financial Consulting held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 11 shares worth $911. The position accounts for ﹤0.01% of the portfolio, ranked #1019.

Ares Financial Consulting first reported a position in ANIP in Q4 2025 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Ares Financial Consulting held 11 shares of ANI Pharmaceuticals worth $911 as of Q2 2026.
  • Ares Financial Consulting left its ANI Pharmaceuticals share count unchanged in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1019 holding.
  • Ares Financial Consulting first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.